Get 50% OFF This Monsoon!

Advertisement
AdvertisementAdvertisement
logo

Alembic

ALEMBICLTD
Small Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement
AdvertisementAdvertisement

Alembic Share price and Fundamental Analysis

View All Details
View All Details
Alembic Ltd is one of the India's most experienced manufactures of bulk drugs and pharmaceuticals formulation in human and animal healthcare. The Company operates primarily in three lines of business, manufacture of Bulk Drugs, Real Estate and Power Generation through Windmills and Co-gen Power Plant which is presently used for captive consumption for the operation of the Bulk Drugs Manufacturing plant at Vadodara. The Company has been dealing in Active Pharmaceutical Ingredient (API) Business and Real Estate Business.
Company Incorporation1907
ChairmanChirayu R Amin
Head QuartersNA
Previous NameNA

Key Metrics

Market Cap (Cr)
3,069.83
PE Ratio
9.88
Industry P/E
39.71
PEG Ratio
0.63
ROE
13.28%
ROCE
6.68%
ROA
5.78%
Total Debt (Cr)
14.45
Debt to Equity
0.01
Dividend Yield
2.01%
EPS
12.1
Book Value & P/B
33.23 x 3.6
Face Value
2
Outstanding Shares(Cr)
25.68
Current Ratio
1.92
EV to Sales
13.88

Included In

+More

Stock Returns

1 Week+7.52%
1 Month+14.56%
6 Months-19.02%
1 Year+15.98%
3 Years+99.87%
5 Years+47.71%

CAGR

1 Year CAGR

Revenue Growth

+23.77%

Net Profit Growth

+15.19%

Operating Profit Growth

+18.78%

Dividend Growth

+9.09%

Stock Returns CAGR

+16.77%
no_data

No Stocks

Smart Score

2.3
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

/ View Standalone
PARTICULARS

Total Revenue

Total Expenses

Operating Expense

Operating Profit

Interest

Depreciation & Amortization

Profit Before Tax

Tax

Profit after tax

Adj EPS in Rs - Basic

Adj EPS in Rs - Diluted

Profit and Loss Statement

/ View Standalone
Credit Rating
Director Report
Chairman Report
Auditor Report

Balance sheet

/ View Standalone

Cashflow Statement

/ View Standalone
Mar 25

Promoters : 70.88%

FIIs : 1.66%

DIIs : 0.05%

Public : 27.41%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 0.0% of holding in March 2025 Qtr
FII Shareholding Decreased by 0.13% to 1.66% in March 2025 Qtr
DII Shareholding Decreased by 0.01% to 0.05% in March 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Alembic Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Alembic Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Alembic Ltd is one of the India's most experienced manufactures of bulk drugs and pharmaceuticals formulation in human and animal healthcare. The Company operates primarily in three lines of business, manufacture of Bulk Drugs, Real Estate and Power Generation through Windmills and Co-gen Power Plant which is presently used for captive consumption for the operation of the Bulk Drugs Manufacturing plant at Vadodara. The Company has been dealing in Active Pharmaceutical Ingredient (API) Business and Real Estate Business.

The company is a ISO-9002 and ISO-14001 certified company with manufacturing practices and facilities that conform to WHO-GMP guidelines. They manufacture pharmaceuticals and chemicals, bulk drugs (penicillin and other antibiotics) and formulations. They are having their manufacturing facilities at Vadodara in Gujarat and Solan in Himachal Pradesh.

Alembic Ltd was incorporated in the year 1907 with the name Alembic Chemical Works Co Ltd in Vadodara to manufacture tinctures and alcohol. They Started to manufacture cough syrup, vitamins, tonics and sulphur durgs in the year 1940. In the year 1961, they inaugrated the Pencillin Palnt. In the year 1968, they started to manufacture Streptomycin.

In the 1971, they manufactured Erythromycin using expertise from Eli Lilly, USA and in the year 1972, they launched Althrocin, a brand of Erythromycin. In year 1997, Althrocin become top selling brand in India. In the year 2001, they started to manufacture Cephalosporin C. In June 2001, the company formed a wholly owned subsidiary company named Alembic Europe Pvt Ltd in UK.

In the year 2005, the company has launched ZERO, a new generation, no calories, Sucralose Based Sugar Substitute which gave entry for the company into the high-growth lifestyle OTC product segment. In May 2005, the generic alliances and API division were merged to form an independent SBU.

The company has set up a formulation manufacturing facility at Baddi in Himachal Pradesh with a production capacity 900 million tablets and 600 million liquid oral bottles annually. During the year 2005-06, the company has increased the installed capacity of Tablets & Capsules and Oral Preparation & Ointments by 595 Million Nos and 720 MT respectively.

During the year 2005-06, the company acquired API Plant at Karakhadi in Vadodara. In the year 2007, the company acquired the Non-Oncology Business of Dabur Pharma Ltd. Also in the same year, they entered into a licensing agreement for its Novel Drug Delivery Platform for Keppra XR with UCB Belgium. During the year 2007-08, the company acquired the API manufacturing facility of Nirayu Pvt Ltd at Panelav near Vododara.

The Company formed a wholly owned subsidiary viz. Alembic Global Holding SA in Neuchatel, Switzerland in 2009. The 'Pharmaceutical Undertaking' of the Company demerged and the same got transferred to Alembic Pharmaceuticals Limited with effect from Appointed date i.e. 1st April, 2010. The maiden real estate project -'Samsara' was completed in 2014.

The Company launched second real estate project, VEDA in 2015-16. It further launched two API's in 2017. During year 2017-18, Alembic City Limited (formerly known as Alembic Exports Limited) became wholly-owned subsidiary of the Company.

During 2018-19, the Composite Scheme of Arrangement comprising of transfer and vesting of the Identified Real Estate Undertaking of Alembic Limited (the Company / the First Demerged Company) into Shreno Limited (the First Transferee Company/ the Second Demerged Company) and transfer and vesting of Engineering Division and Investment Division of Shreno Limited into Nirayu Private Limited (the Second Transferee Company) and their respective shareholders with effect from the Appointed Date i.e. 1st November, 2018 was sanctioned by the Hon'ble National Company Law Tribunal, Ahmedabad Bench (NCLT') vide its order dated 26th July, 2019. Accordingly, Scheme was made effective from 26th July, 2019.

The Company launched a residential project VEDA - II during 2020.

Alembic Share Price

Alembic share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Alembic Market Cap

Market capitalization of Alembic indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Alembic is valued compared to its competitors.

Alembic PE Ratio

Alembic PE ratio helps investors understand what is the market value of each stock compared to Alembic 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Alembic PEG Ratio

The PEG ratio of Alembic evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Alembic ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Alembic generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Alembic ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Alembic in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Alembic Total Debt

Total debt of Alembic shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Alembic Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Alembic compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Alembic CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Alembic over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Alembic Technical Analysis

Technical analysis of Alembic helps investors get an insight into when they can enter or exit the stock. Key components of Alembic Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Alembic shares often struggle to rise above due to selling pressure.

Alembic Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Alembic ’s financial health and profitability.

Alembic Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Alembic Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Alembic Financials

The financials of Alembic provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Alembic Profit and Loss Statements

The profit and loss statement of Alembic highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Alembic .

Alembic Balance Sheet

The balance sheet presents a snapshot of Alembic ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Alembic Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.

Download the App

Download the App